HIVE Blockchain Technologies (CVE:HIV – Get Free Report) was upgraded by analysts at Roth Capital to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.
HIV has been the subject of a number of other research reports. Cantor Fitzgerald upgraded shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Tuesday, October 29th. Northland Capmk upgraded HIVE Blockchain Technologies to a “strong-buy” rating in a research note on Thursday, September 19th.
Check Out Our Latest Report on HIVE Blockchain Technologies
HIVE Blockchain Technologies Price Performance
See Also
- Five stocks we like better than HIVE Blockchain Technologies
- What Are Dividend Contenders? Investing in Dividend Contenders
- Why Wall Street Sees Major Upside for PayPal Stock
- Stock Dividend Cuts Happen Are You Ready?
- Cintas Shares Slide: A Prime Opportunity to Buy the Dip
- How to Invest in Biotech Stocks
- Tempus AI: A Potential Double-Bagger After Recent Pullback
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
